Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210

Joo, 1974, Cholera vaccines, 333 Finkelstein, 1984, Cholera, 107 Glass, 1982, Endemic cholera in rural Bangladesh, 1966–1980, Am J Epidemiol, 116, 959, 10.1093/oxfordjournals.aje.a113498 Levine, 1981, Duration of infection-derived immunity to cholera, J Infect Dis, 143, 818, 10.1093/infdis/143.6.818 Holmgren, 1989, New cholera vaccines, Vaccine, 7, 94, 10.1016/0264-410X(89)90042-X Holmgren, 1977, Development of improved cholera vaccine based on subunit toxoid, Nature, 269, 602, 10.1038/269602a0 Levine, 1988, Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR, Lancet, ii, 467, 10.1016/S0140-6736(88)90120-1 Germanier, 1984, Typhoid fever, 137 Neoh, 1972, Protection of infant mice against cholera by antibodies to three antigens of Vibrio cholerae, J Infect Dis, 126, 41, 10.1093/infdis/126.1.41 Cash, 1974, Response of man to infection with Vibrio cholerae II. Protection from illness afforded by previous disease and vaccine, J Infect Dis, 130, 325, 10.1093/infdis/130.4.325 Levine, 1979, Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity, Trans R Soc Trop Med Hyg, 73, 3, 10.1016/0035-9203(79)90119-6 Mosley, 1969, Report of the 1966–1967 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population—the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae, Bull WHO, 40, 187 Neoh, 1970, The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement, J Infect Dis, 121, 505, 10.1093/infdis/121.5.505 Manning, 1986, Molecular cloning and expression in Escherichia coli K-12 of the O-antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae O1 lipopolysaccharides and their potential for vaccine development, Infect Immun, 53, 272, 10.1128/IAI.53.2.272-277.1986 Germanier, 1983, Characteristics of the attenuated oral vaccine strain S. typhi Ty21a, Dev Biol Standard, 53, 3 Keleti, 1974, 74 Lindberg, 1977, Bacterial surface carbohydrates and bacteriophage adsorption, 289 Van der Ley, 1986, O-antigenic chains of lipopolysaccharide prevent binding of antibody molecules to an outer membrane pore protein in Enterobacteriaceae, Microbial Pathogenesis, 1, 43, 10.1016/0882-4010(86)90030-6 Bently, 1988, Effect of lipopolysaccharide structure on reactivity of antiporin monoclonal antibodies with the bacterial cell surface, J Bacteriol, 170, 1063, 10.1128/jb.170.3.1063-1068.1988 Seid RC, Kopecko DJ, Sadoff JC, Schneider H, Baron LS, Formal SB. Unusual lipopolysaccharide antigens of Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J Biol Chem; 259: 9028-34. Forrest, 1988, The development of a bivalent vaccine against diarrhoeal disease, South East Asian J Trop Med Pub Hlth, 19, 449 Hone, 1988, A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans, Infect Immun, 56, 1326, 10.1128/IAI.56.5.1326-1333.1988 Attridge, 1983, Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae, J Infect Dis, 148, 931, 10.1093/infdis/148.5.931 Steinbuch, 1969, The isolation of IgG from mammalian sera with the aid of caprylic acid, Arch Biochem Biophys, 134, 279, 10.1016/0003-9861(69)90285-9 Sharma, 1989, Significance of toxin-coregulated pili as protective antigens of Vibrio cholerae in the infant mouse model, Vaccine, 7, 451, 10.1016/0264-410X(89)90161-8 Ward, 1987, A physical map of the chromosomal region determining O-antigen biosynthesis in Vibrio cholerae 01, Gene, 55, 197, 10.1016/0378-1119(87)90280-0